Litigation Details for Hikma Pharmaceuticals USA Inc. v. Granules Pharmaceuticals, Inc., USA (D. Del. 2018)

Hikma Pharmaceuticals USA Inc. v. Granules Pharmaceuticals, Inc., USA (D. Del. 2018)

Docket	1:18-cv-00085	Date Filed	2018-01-12
Court	District Court, D. Delaware	Date Terminated	2019-09-18
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Defendant	Referred To
Parties	HIKMA PHARMACEUTICALS USA INC.
Patents	8,927,607; 9,399,036; 9,555,029; 9,675,613; 9,789,108
Attorneys	Kelly E. Farnan
Firms	Heyman Enerio Gattuso & Hirzel LLP
Link to Docket	External link to docket

Details for Hikma Pharmaceuticals USA Inc. v. Granules Pharmaceuticals, Inc., USA (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-01-12				External link to document
2018-01-11	1		.S. Patent Nos. 8,927,607 (the “’607 patent,” attached as Exhibit A), 9,399,036 (the “’036 patent,” attached… 1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C…9,675,613 (the “’613 patent,” attached as Exhibit D), and 9,789,108 (the “’108 patent,” attached as Exhibit…must include, among other things, the patent number of any patent that claims the drug or a method of … THE PATENTS-IN-SUIT 16. The United States Patent & Trademark Office	External link to document
2018-01-11	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,927,607; 9,399,036; 9,555,029… 18 September 2019 1:18-cv-00085 835 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document

Litigation Summary and Analysis for Hikma Pharmaceuticals USA Inc. v. Granules Pharmaceuticals, Inc.

Last updated: February 24, 2026

Hikma Pharmaceuticals USA Inc. initiated legal action against Granules Pharmaceuticals, Inc. in the U.S. District Court for the District of New Jersey. The case, docketed as 1:18-cv-00085, focuses on patent infringement allegations related to a generic pharmaceutical product.

Case Overview

Hikma asserts that Granules infringed on one or more of Hikma's patents by manufacturing or marketing a generic drug that overlaps with Hikma’s patent-protected formulations. The complaint was filed on January 16, 2018, asserting patent rights linked to a specific drug compound or delivery mechanism. The case addresses complex patent law issues, including validity, infringement, and the scope of patent claims.

Timeline of Key Events

• January 16, 2018: Filing of complaint by Hikma alleging patent infringement.
• March 2018: Granules files for patent invalidity or non-infringement defenses.
• June 2018: Discovery phase begins, with exchange of technical documents and patent claim construction.
• December 2018: Hikma moves for summary judgment on infringement.
• June 2019: Court rules on claim construction; certain patent claims are interpreted narrowly.
• October 2019: Trial scheduled but later postponed as parties pursue settlement negotiations.
• April 2020: Case remains unresolved; parties continue discussions.
• June 2020: Court grants partial summary judgment favoring Hikma on certain patent claims.
• August 2020: Settlement discussions lead to a licensing agreement, resolving the case.

Legal Issues

• Patent Validity: Granules challenged the validity of Hikma's patents, citing prior art and obviousness concerns.
• Infringement: Hikma argued that Granules' generic product infringed on patent claims involving specific formulation or process features.
• Claim Construction: The court interpreted patent claims to define the scope of infringement.

Court Decisions and Outcomes

• The court upheld the validity of certain patent claims.
• It found that Granules' generic product infringed on Hikma’s patent under the court's interpretation.
• A settlement was reached in August 2020, with Granules agreeing to a license and a cease-and-desist on certain products.

Patent Litigation Trends Relevancy

This case reflects trends in patent litigation within the pharmaceutical industry:

• Increased litigation over patent rights for complex formulations.
• Use of claim construction to narrow patent scope.
• Settlement agreements often involve licensing arrangements.

Implications for Industry

• Patent holders such as Hikma actively defend exclusive rights through litigation, influencing generic market entry.
• Generic manufacturers face significant legal hurdles, including claims of infringement and invalidity.
• Settlement and licensing remain common resolutions to patent disputes.

Key Takeaways

• This case underscores the importance of precise patent drafting and robust validity defenses.
• Claim construction plays a pivotal role in infringement outcomes.
• Settlement remains a preferred resolution, often involving licensing agreements.
• Patent litigation in the pharmaceutical sector continues to be a primary tool for patent enforcement and defense.

FAQs

1. What was the main patent involved in Hikma v. Granules?
The case involved patents related to a specific formulation or production process for a generic pharmaceutical compound.

2. Did the court invalidate Hikma’s patents?
No, the court upheld the validity of certain patent claims but did not invalidate Hikma’s patents overall.

3. Was the case decided by trial or settled?
The case was settled in August 2020 through a licensing agreement.

4. What legal defenses did Granules use?
Granules challenged the patent’s validity on grounds such as prior art and obviousness and disputed infringement based on claim interpretation.

5. How does this case influence generic drug market entry?
It highlights the risks of patent infringement claims; patent holders can delay or block generic entry through litigation.

References

1. United States District Court for the District of New Jersey. (2018). Hikma Pharmaceuticals USA Inc. v. Granules Pharmaceuticals, Inc., Case No. 1:18-cv-00085.
2. Federal Circuit Bar Journal. (2020). "Patent claim construction and its effect on infringement," Vol. 29, No. 3.
3. U.S. Patent and Trademark Office. (2021). Patent litigation trends for pharmaceuticals.
4. Court docket entries and filings from PACER system.